Oak Ridge, TN, May 25, 2023 (GLOBE NEWSWIRE) — DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 […]
Financial
Medtronic reports full year and fourth quarter fiscal 2023 financial results; announces dividend increase
Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company DUBLIN, May 25, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2023, which ended April 28, 2023. Fourth Quarter (Q4) Key Highlights Q4 revenue of $8.5 billion increased 5.6% as reported and […]
Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure
TOKYO–(BUSINESS WIRE)–Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 2 billion JPY at Series D round, bringing its total financial backing to 10.2 billion JPY (approx. $74 million) since it was founded in 2015. New investors are Japan Co-Invest […]
SANUWAVE Health, Inc. Appoints Morgan Frank as Chief Executive Officer
Frank Brings 29 Years of Experience in Life Sciences, Technology, and Capital Markets Kevin Richardson to Remain at SANUWAVE as Chief Strategic Officer and as a Member of the Board of Directors EDEN PRAIRIE, MN, May 24, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB:SNWV), a […]
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 22, 2023, the compensation committee of the company’s board of directors granted two new […]
Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share […]
Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering
Oak Ridge, TN, May 22, 2023 (GLOBE NEWSWIRE) — DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 […]
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of Global Marketing […]
Microbot Medical to Enhance Focus on its Core Business and Prioritize Preparations for Regulatory and First in Human Clinical Cases
Company will enable focus on its LIBERTY technology through the introduction of the Core Business Focus Program coupled with cost restructuring to support it HINGHAM, Mass., May 18, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, […]
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update. First Quarter 2023 and Recent Corporate and Operational Highlights Continued reducing expenses to conserve cash […]


